CEO acquires call options from Stena Sessan

CEO acquires call options from Stena Sessan

Meda's CEO, CFO and two other group executives have acquired a total of 600,000
call options from Stena Sessan; these options have a two-year duration, and they
entitle the holder to buy 600,000 Meda shares at SEK 80 per share (exercise
price). Dilution will not occur for other Meda shareholders because these call
options were issued on Stena Sessan's shareholding. 
Stena Sessan is Meda's largest shareholder. The Black & Scholes valuation model
was used to determine the price of these call options. 


For more information contact:

Anders Larnholt, VP Investor Relations	tel. +46 709 458 878

MEDA AB (publ) is a leading international specialty pharma company. The company
specialises in marketing and pharmaceutical development in late clinical stage.
Acquisitions and long-term partnerships drive the company's strategy. Meda is
represented by its own organizations in about 40 countries. Meda's products are
sold in 120 countries worldwide. The Meda share is listed under Large Cap on the
Nasdaq OMX Nordic Stock Exchange Stockholm. Find out more, visit www.meda.se.